Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared an article on X:
“As shown in previous CRC studies, ctDNA positivity captures relapse risk very well. However, ALTAIR does not show that we can meaningfully and durably modify this risk with FTD/TPI. Therefore, in this setting, ctDNA does not appear to function as a predictive tool for treatment selection, but rather as a strong MRD/prognostic enrichment marker.
Trying to treat MRD with conventional chemotherapy may not be the most rational approach. The biology of circulating tumor cells or molecular residual disease may differ from that of established tumor deposits in tissue.
We need treatment strategies designed specifically around MRD biology, rather than simply moving standard cytotoxic agents earlier into the molecular recurrence setting.”
Title: Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial
Authors: Hideaki Bando, Jun Watanabe, Yusuke Takahashi, Masahito Kotaka, Nobuhisa Matsuhashi, Eiji Oki, Yoshito Komatsu, Manabu Shiozawa, Keiji Hirata, Yuji Miyamoto, Masanobu Takahashi, Kentaro Yamazaki, Dai Manaka, Akiyoshi Kanazawa, Yi-Hsin Liang, Kun-Huei Yeh, Yuko Watsuji, Yuko Yamamoto, Makoto Fukui, Shruti Sharma, Vasily Aushev, Adham Jurdi, Matthew Rabinowitz, Minetta Liu, Takeshi Kato
Read the Full Article.
Other articles featuring Yakup Ergün on OncoDaily.